Louis J. Arcudi
President bij Millendo Therapeutics US, Inc.
Actieve functies van Louis J. Arcudi
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | President | - | - |
Treasurer | - | - |
Loopbaan van Louis J. Arcudi
Eerdere bekende functies van Louis J. Arcudi
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MILLENDO THERAPEUTICS | Directeur/Bestuurslid | 01-02-2021 | 25-06-2021 |
Algemeen Directeur | 01-02-2021 | 25-06-2021 | |
Financieel Directeur/CFO | 01-11-2018 | 01-02-2021 | |
President | 01-02-2021 | 25-06-2021 | |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Comptroller/Controller/Auditor | 01-12-2007 | 31-10-2018 |
Operationeel Directeur | 01-12-2007 | 31-10-2018 | |
Financieel Directeur/CFO | 01-12-2007 | 31-10-2018 | |
Investor Relations Contact | 01-12-2007 | 02-12-2014 | |
Bedrijfssecretaris | 01-12-2007 | - | |
Treasurer | 01-12-2007 | 31-10-2018 | |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Hoofd Administratief Officier | 01-06-2002 | 01-12-2007 |
Financieel Directeur/CFO | 01-06-2002 | 01-12-2007 | |
Treasurer | 01-06-2002 | 01-12-2007 | |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Molecular Oncology is a company that develops novel cancer therapeutics and diagnostics. The company is based in Cambridge, MA. The company was founded by Gail J. Maderis. | Hoofd Administratief Officier | 01-01-2000 | 01-01-2003 |
Financieel Directeur/CFO | 01-01-2000 | 01-01-2003 | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | 01-01-2003 | 01-01-2003 |
Financieel Directeur/CFO | 01-01-2003 | 01-01-2003 | |
COGNEX CORPORATION | Comptroller/Controller/Auditor | - | - |
Opleiding van Louis J. Arcudi
Bryant University | Masters Business Admin |
Southern New Hampshire University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 10 |
Operationeel
Director of Finance/CFO | 5 |
Treasurer | 3 |
Comptroller/Controller/Auditor | 2 |
Sectoraal
Health Technology | 7 |
Consumer Services | 3 |
Electronic Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
COGNEX CORPORATION | Electronic Technology |
Bedrijven in privébezit | 6 |
---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Genzyme Molecular Oncology
Genzyme Molecular Oncology Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Molecular Oncology is a company that develops novel cancer therapeutics and diagnostics. The company is based in Cambridge, MA. The company was founded by Gail J. Maderis. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
- Beurs
- Insiders
- Louis J. Arcudi
- Ervaring